Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Vitamin E & Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Elafibranor
1.2.5 Selonsertib & Cenicriviroc
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2018-2033)
2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Region
2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2018-2023)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2024-2033)
2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2018-2023)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2018-2023)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2024-2033)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2018-2023)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2033)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2033)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2033)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2033)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2033)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Conatus Pharmaceuticals
11.2.1 Conatus Pharmaceuticals Company Detail
11.2.2 Conatus Pharmaceuticals Business Overview
11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.2.5 Conatus Pharmaceuticals Recent Development
11.3 Enzo Biochem
11.3.1 Enzo Biochem Company Detail
11.3.2 Enzo Biochem Business Overview
11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.3.5 Enzo Biochem Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Detail
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Genfit
11.5.1 Genfit Company Detail
11.5.2 Genfit Business Overview
11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.5.5 Genfit Recent Development
11.6 Gilead
11.6.1 Gilead Company Detail
11.6.2 Gilead Business Overview
11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.6.5 Gilead Recent Development
11.7 Horizon Pharma
11.7.1 Horizon Pharma Company Detail
11.7.2 Horizon Pharma Business Overview
11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.7.5 Horizon Pharma Recent Development
11.8 Immuron
11.8.1 Immuron Company Detail
11.8.2 Immuron Business Overview
11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.8.5 Immuron Recent Development
11.9 Intercept Pharmaceuticals
11.9.1 Intercept Pharmaceuticals Company Detail
11.9.2 Intercept Pharmaceuticals Business Overview
11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.9.5 Intercept Pharmaceuticals Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Vitamin E & Pioglitazone
Table 3. Key Players of Obeticholic Acid (OCA)
Table 4. Key Players of Elafibranor
Table 5. Key Players of Selonsertib & Cenicriviroc
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2023)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2024-2033)
Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2018-2023)
Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 23. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2024-2033)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2024-2033)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 48. AstraZeneca Company Detail
Table 49. AstraZeneca Business Overview
Table 50. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 51. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 52. AstraZeneca Recent Development
Table 53. Conatus Pharmaceuticals Company Detail
Table 54. Conatus Pharmaceuticals Business Overview
Table 55. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 56. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 57. Conatus Pharmaceuticals Recent Development
Table 58. Enzo Biochem Company Detail
Table 59. Enzo Biochem Business Overview
Table 60. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 61. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 62. Enzo Biochem Recent Development
Table 63. Galmed Pharmaceuticals Company Detail
Table 64. Galmed Pharmaceuticals Business Overview
Table 65. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 66. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 67. Galmed Pharmaceuticals Recent Development
Table 68. Genfit Company Detail
Table 69. Genfit Business Overview
Table 70. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 71. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 72. Genfit Recent Development
Table 73. Gilead Company Detail
Table 74. Gilead Business Overview
Table 75. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 76. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 77. Gilead Recent Development
Table 78. Horizon Pharma Company Detail
Table 79. Horizon Pharma Business Overview
Table 80. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 81. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 82. Horizon Pharma Recent Development
Table 83. Immuron Company Detail
Table 84. Immuron Business Overview
Table 85. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 86. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 87. Immuron Recent Development
Table 88. Intercept Pharmaceuticals Company Detail
Table 89. Intercept Pharmaceuticals Business Overview
Table 90. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 91. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 92. Intercept Pharmaceuticals Recent Development
Table 93. Novo Nordisk Company Detail
Table 94. Novo Nordisk Business Overview
Table 95. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product
Table 96. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023) & (US$ Million)
Table 97. Novo Nordisk Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2022 VS 2033
Figure 3. Vitamin E & Pioglitazone Features
Figure 4. Obeticholic Acid (OCA) Features
Figure 5. Elafibranor Features
Figure 6. Selonsertib & Cenicriviroc Features
Figure 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2022 VS 2033
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Online Provider Case Studies
Figure 11. Retail Pharmacy Case Studies
Figure 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region: 2022 VS 2033
Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2022
Figure 17. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2033)
Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2033)
Figure 25. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2018-2033)
Figure 33. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2033)
Figure 41. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2018-2033)
Figure 45. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 48. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 49. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 50. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 51. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 52. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 53. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 54. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 55. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 56. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed